Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis
Lupus Erythematosus, Systemic

Interventions: Drug: cyclophosphamide
Drug: abatacept
Drug: azathioprine
Drug: abatacept placebo
Drug: prednisone
Drug: azathioprine placebo

First Posted Date: 2008-10-17

Last Posted Date: 2016-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 137

Registration Number: NCT00774852

Locations: 🇺🇸
Feinstein Institute, Manhasset, New York, United States
🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States

and more 20 locations

Immune Parameters in the Cord Blood of Newborns Exposed to Malaria in the Womb

Completed

Conditions: Malaria

First Posted Date: 2008-10-15

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT00772642

Locations: 🇲🇱
Malaria Research and Training Center, Bamako, Mali

Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation

Phase 1

Completed

Conditions: Kidney Failure, Chronic
Kidney Transplantation
Immunosuppression

Interventions: Drug: Sirolimus
Drug: MMF or Azathioprine

First Posted Date: 2008-10-08

Last Posted Date: 2013-02-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 7

Registration Number: NCT00768729

Locations: 🇺🇸
Children's Hospital, Boston, Boston, Massachusetts, United States
🇺🇸
Children's Hospital, Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital of Central California, Madera, California, United States

and more 2 locations

Analysis of HIV-1 Replication During Antiretroviral Therapy

Conditions: HIV

First Posted Date: 2008-10-07

Last Posted Date: 2025-05-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 70

Registration Number: NCT00767312

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Vicriviroc

First Posted Date: 2008-10-06

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 9

Registration Number: NCT00766597

Locations: 🇺🇸
Chicago Children's CRS, Chicago, Illinois, United States
🇵🇷
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico
🇺🇸
Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States

and more 6 locations

High Dose Influenza in Immunosuppressed Subjects

Phase 2

Withdrawn

Conditions: Influenza

Interventions: Biological: Trivalent inactivated influenza vaccine
Biological: Trivalent Baculovirus-expressed Influenza HA vaccine

First Posted Date: 2008-10-03

Last Posted Date: 2015-08-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00766285

Locations: 🇺🇸
The University of Texas - MD Anderson Cancer Center - Infectious Diseases, Houston, Texas, United States

Malaria Challenge With NF54 Strain

Phase 1

Completed

Conditions: Plasmodium Falciparum Infection

Interventions: Biological: NF54 P. falciparum isolate

First Posted Date: 2008-08-29

Last Posted Date: 2014-08-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 37

Registration Number: NCT00744133

Locations: 🇺🇸
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States

Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections

Phase 4

Terminated

Conditions: HIV
Hepatitis C
Liver Disease
Fatty Liver
Steatosis

Interventions: Drug: Pioglitazone
Drug: Placebo

First Posted Date: 2008-08-27

Last Posted Date: 2016-12-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 13

Registration Number: NCT00742326

Locations: 🇺🇸
VA Medical Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Malaria Vaccine for Children in Mali

Phase 1

Completed

Conditions: Malaria
Malaria Infection

First Posted Date: 2008-08-22

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT00740090

Locations: 🇲🇱
Malaria Research and Training Center, Bamako, Mali

Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine

Phase 1

Completed

Conditions: Influenza
Virus Diseases

Interventions: Biological: H6N1 Teal HK 97/AA ca recombinant vaccine

First Posted Date: 2008-08-14

Last Posted Date: 2009-08-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 22

Registration Number: NCT00734175

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center, CIR Unit at the Mason F Lord Building, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy